Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma keeps profit forecast as prostate cancer drug sales rise

01/31/2020 | 03:29am EST
FILE PHOTO: Astellas Pharma's logo is pictured at its headquarters in Tokyo

Japan's Astellas Pharma Inc reiterated its full-year operating profit forecast on Friday, as a jump in sales of its prostate cancer drug Xtandi countered overseas acquisition costs.

The company said it expects an operating profit of 263 billion yen ($2.4 billion) for the year ending March 31, higher than analysts' average expectation of 256 billion yen, according to IBES data from Refinitiv. Astellas reported an annual operating profit of 244 billion yen last year.

Shares in the company closed 2.4% higher in Tokyo compared with a 1% rise in the broader market.

Sales of Xtandi rose 18% to 298 billion yen in the third quarter ended Dec. 31.

However, core operating profit for the quarter was 3.3% lower, hurt partly by a 2.5% drop in revenue from Prograf, used to prevent rejection of organ transplants.

The company also said it will book a one-off charge of about $100 million in the fourth quarter related to its purchase of U.S.-based biotech Audentes Therapeutics Inc.

Astellas, the country's second-biggest drugmaker by sales, has ramped up overseas acquisitions to broaden its drug pipeline.

The company said in December it would pay up to $665 billion for Xyphos Biosciences Inc to expand its immuno-oncology business. Earlier that month, Astellas said it would purchase Audentes in a deal worth $2.65 billion to expand into genetic medicines.

Both Xyphos and Audentes are based in San Francisco, a hub for biotech companies that are fetching huge premiums for global pharma firms eager to bolster their drug pipelines.

Among other major Japanese pharma companies reporting earnings, Daiichi Sankyo Co, Japan's fourth-largest drug company by sales, raised its full-year operating profit forecast, citing lower taxes. It expects to earn 135 billion yen in the year ending March 31 versus 125 billion predicted in October.

Eisai Co, the partner of Biogen Inc on Alzheimer's disease drug candidate aducanumab, maintained its full-year operating profit forecast at 110 billion yen, a 16% increase from last year, driven by sales of its cancer drug Lenvima.

Daiichi Sankyo shares rose 1.6% while Eisai gained 2.2%.

By Rocky Swift


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 2.08% 1720 End-of-day quote.7.90%
BIOGEN INC. -2.40% 265.15 Delayed Quote.8.29%
DAIICHI SANKYO COMPANY, LIMITED 0.17% 3586 End-of-day quote.1.44%
EISAI CO., LTD. 2.84% 7850 End-of-day quote.6.48%
HUB CO., LTD. 2.81% 622 End-of-day quote.14.76%
SANKYO CO., LTD. 2.15% 2940 End-of-day quote.5.38%
All news about ASTELLAS PHARMA INC.
01/26ASTELLAS PHARMA : Builds New Manufacturing Lines for Aseptic Drugs at Yaizu Tech..
MT
01/25ASTELLAS PHARMA INC. : - Establishing New Manufacturing Lines for Aseptic Drug P..
AQ
01/25Japanese shares gain tracking U.S. futures; tech and pharma stocks boost
RE
01/25Japanese shares track U.S. futures higher, tech leads gains
RE
01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
AQ
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
AQ
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
MT
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
AQ
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
AQ
2020ASTELLAS PHARMA INC. : - Expansion of the Domestic Logistics Platform for Pharma..
AQ
More news
Financials
Sales 2021 1 269 B 12 164 M 12 164 M
Net income 2021 180 B 1 726 M 1 726 M
Net cash 2021 441 B 4 230 M 4 230 M
P/E ratio 2021 17,7x
Yield 2021 2,42%
Capitalization 3 233 B 31 065 M 30 984 M
EV / Sales 2021 2,20x
EV / Sales 2022 2,02x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 229,17 JPY
Last Close Price 1 740,50 JPY
Spread / Highest target 107%
Spread / Average Target 28,1%
Spread / Lowest Target -5,20%
EPS Revisions
Managers and Directors
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.7.90%31 060
JOHNSON & JOHNSON6.67%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.-1.55%207 384
MERCK & CO., INC.-1.89%203 035